SHMT2 and cancer: Accumulating evidence positions SHMT2 and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) — the first and second enzymes in mitochondrial serine catabolism — as independent prognostic markers and potential therapeutic targets across multiple cancer types (40–45).